Guiding mRNA-LNP Drug Products from Early R&D to the Market

Andreas Wagner, Ph.D., Head of Liposome Technology, Polymun Scientific GmbH

Guiding mRNA-LNP Drug Products from Early R&D to the Market

Click video to watch

Andreas Wagner, Ph.D., Head of Liposome Technology, Polymun Scientific GmbH
Dr Andreas Wagner is Head of Liposome Technology at Polymun Scientific GmbH. He has significant expertise formulation of liposomes and LNPs and development of the respective processes for their clinical use. He and the team at Polymun Scientific have significantly contributed to the 1st successful mRNA vaccine Comirnaty by optimizing and up-scaling the LNP process as well as by supporting clinical and early market supply of the successful Covid-19 vaccine.

Dr Andreas Wagner is Head of Liposome Technology at Polymun Scientific GmbH. He has significant expertise formulation of liposomes and LNPs and development of the respective processes for their clinical use. He and the team at Polymun Scientific have significantly contributed to the 1st successful mRNA vaccine Comirnaty by optimizing and up-scaling the LNP process as well as by supporting clinical and early market supply of the successful Covid-19 vaccine.